 |
|
Study suggests use of stem cell transplantation is beneficial treatment of type 1 diabetes
April 11, 2007A therapy that includes stem cell transplantation induced extended insulin independence in patients with type 1 diabetes mellitus, according to a preliminary study in the April 11 issue of JAMA.
Type 1 diabetes mellitus (DM) results from a cell-mediated autoimmune attack against pancreatic beta cells. At the time of clinical diagnosis, approximately 60 percent to 80 percent of the beta-cell mass has been destroyed, according to background information in the article. Beta-cell preservation has been shown to be an important target in the management of type 1 DM and in the prevention of its related complications.
Julio C. Voltarelli, M.D., Ph.D., of the University of São Paulo, Ribeirão Preto, Brazil, in collaboration with Richard Burt, M.D., of the Northwestern University Feinberg School of Medicine, Chicago, and colleagues conducted a study to examine the effect of high-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation (AHST) to preserve beta-cell function in 15 newly diagnosed patients with type 1 DM. AHST, which uses a patient's own blood stem cells, involves the removal and treatment of the stem cells, and their return to the patient by intravenous injection.
During a 7 to 36-month follow-up, 14 patients became insulin-free (one for 35 months, four for at least 21 months, seven for at least six months; and two with late response were insulin-free for one and five months, respectively). Among those, one patient resumed insulin use one year after AHST. The only severe adverse effects were pneumonia in one patient and endocrine dysfunction in two others.
"This is, to our knowledge, the first report of high-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation for human type 1 DM. Very encouraging results were obtained in a small number of patients with early-onset disease. Ninety-three percent of patients achieved different periods of insulin independence and treatment-related toxicity was low, with no mortality. Further follow-up is necessary to confirm the duration of insulin independence and the mechanisms of action of the procedure. In addition, randomized controlled trials and further biological studies are necessary to confirm the role of this treatment in changing the natural history of type 1 DM and to evaluate the contribution of hematopoietic stem cells to this change," the authors conclude.
JAMA and Archives Journals
During a 7 to 36-month follow-up, 14 patients became insulin-free (one for 35 months, four for at least 21 months, seven for at least six months; and two with late response were insulin-free for one and five months, respectively). Among those, one patient resumed insulin use one year after AHST. The only severe adverse effects were pneumonia in one patient and endocrine dysfunction in two others.
"This is, to our knowledge, the first report of high-dose immunosuppression followed by autologous nonmyeloablative hematopoietic stem cell transplantation for human type 1 DM. Very encouraging results were obtained in a small number of patients with early-onset disease. Ninety-three percent of patients achieved different periods of insulin independence and treatment-related toxicity was low, with no mortality. Further follow-up is necessary to confirm the duration of insulin independence and the mechanisms of action of the procedure. In addition, randomized controlled trials and further biological studies are necessary to confirm the role of this treatment in changing the natural history of type 1 DM and to evaluate the contribution of hematopoietic stem cells to this change," the authors conclude.
JAMA and Archives Journals
Cell Transplantation News and Current Cell Transplantation Events RSSPredicting acute GVHD by gene expression could improve liver stem cell transplant outcomes
Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD).
Nerve cells derived from stem cells and transplanted into mice may lead to improved brain treatments
Scientists at the Burnham Institute for Medical Research have, for the first time, genetically programmed embryonic stem (ES) cells to become nerve cells when transplanted into the brain, according to a study published today in The Journal of Neuroscience.
Menstrual blood -- a valuable source of multipotential stem cells?
Researchers seeking new and more abundant sources of stem cells for use in regenerative medicine have identified a potentially unlimited, noncontroversial, easily collectable, and inexpensive source - menstrual blood.
Chemotherapy causes delayed severe neural damage
Cancer treatment with chemotherapeutic agents is often associated with delayed adverse neurological consequences - an occurrence often referred to as "chemobrain" - that may compromise the quality of life of a proportion of cancer survivors.
Coming soon: Cell therapies for diabetes, cancer?
Therapies using stem cell transplants are advancing promising treatments for such conditions as Alzheimer's Disease, neurological diseases and spinal cord injury, and heart disease.
Adult stem cells may be beneficial for certain cardiovascular disorders and autoimmune diseases
A review of previously published research suggests that stem cells harvested from an adult's blood or marrow may provide treatment benefit to select patients for some autoimmune diseases and cardiovascular disorders.
Engineers Use Blood's Hydrodynamics to Manipulate Stem, Cancer Cells
A tiny, implantable device has pulled adult stem cells out of a living rat with a far greater purity than any present technique.
Ireland Cancer Center researchers advance stem cell gene therapy
Ireland Cancer Center of University Hospitals Case Medical Center researchers have recently made great strides in stem cell gene therapy research by transferring a new gene to cancer patients, via their own stem cells, with the ultimate goal of being able to use stronger chemotherapy treatment with less severe side effects.
Vaccine improves event-free survival for leukemia patients
Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
PET and Bioluminescent Imaging Aid Evaluation of Stem Cells' Potential for New Ways to Treat Disease
Using positron emission tomography (PET) imaging with bioluminescence-the light produced by a chemical reaction within an organism-researchers are starting to understand the behavior of transplanted or implanted stem cells that may one day be used to develop new treatments for disease.
More Cell Transplantation News Articles
 | Principles of Tissue Engineering, Third Edition by Robert Lanza, Robert Langer, Joseph Vacanti First published in 1997, Principles of Tissue Engineering is the widely recognized definitive resource in the field. The third edition provides a much needed update of the rapid progress that has been achieved in the field, combining the prerequisites for a general understanding of tissue growth and development, the tools and theoretical information needed to design tissues and organs, as well as... |
 | Umbilical Cord Stem Cell Therapy: The Gift of Healing from Healthy Newborns by David A. Steenblock, Anthony G., Ph.D. Payne We are standing at the threshold of a new and exciting medical era-an era of regeneration, rejuvenation, and renewal in which stems cells will set the stage for healing and in some cases, the restoration of injured, diseased, and debilitated tissues and organ. While stem cell therapy is still in its infancy, the field is rich with promise. The debate over the use of embryonic stem cells and... |
 | 100 Questions & Answers About Bone Marrow and Stem Cell Transplantation by Ewa Carrier, Gracy Ledingham This text is a patient-oriented guide to dealing with a bone marrow or stem cell... |
 | Practical Hematopoietic Stem Cell Transplantation Practical Hematopoietic Stem Cell Transplantation is the only comprehensive yet practical guide to the total care of the transplant patient. It provides a ready source of reference to help health care professionals involved in the management of patients requiring bone marrow and stem cell transplantations – covering many of the infections and complications that may arise. An essential,... |
 | Stem Cells: From Benchtop to Bedside Stem cell biology has gained tremendous interest in the recent years, driven by the hope of finding cures for several diseases through transplantation medicine. Various types of stem cells have been identified from preimplantation embryos, the fetus, placenta and adult. The isolation of human embryonic stem cells has been considered the biggest breakthrough of the 21st century. Some of these stem... |
 | Animal Cloning: The Science of Nuclear Transfer (New Biology) by Joseph, Ph.D. Panno |
 | Principles of Tissue Engineering, Second Edition The opportunity that tissue engineering provides for medicine is extraordinary. In the United States alone, over half-a-trillion dollars are spent each year to care for patients who suffer from tissue loss or dysfunction. Although numerous books and reviews have been written on tissue engineering, none has been as comprehensive in its defining of the field. Principles of Tissue Engineering... |
 | Medicines from Animal Cell Culture Medicines from Animal Cell Culture focuses on the use of animal cell culture, which has been used to produce human and veterinary vaccines, interferon, monoclonal antibodies and genetically engineered products such as tPA and erythropoietin. It also addresses the recent dramatic expansion in cell-based therapies, including the use of live cells for tissue regeneration and the culture of stem... |
 | Bone Marrow and Stem Cell Transplantation (Methods in Molecular Medicine) This volume is a compendium of cutting-edge molecular methods for the successful transplantation of hematopoietic stem cells. The availability of genetic profiles for committed and uncommitted stem cells combined with the determination of molecular steps involved in hematopoietic stem cell activation and self-renewal hold tremendous promise for future success in the clinic. Currently, stem cells... |
 | Clinical Bone Marrow and Blood Stem Cell Transplantation The text of this new third edition is significantly revised and updated with 124 chapters on all aspects of autologous, syngeneic, and allogeneic transplantation. Thoroughly referenced through 2003 with a final "breaking news" chapter from this rapidly evolving field, the authoritative and practical text is an essential resource for hematologists, oncologists, and transplant specialists. Second... |
| © 2008 BrightSurf.com |